Department of Endocrinology, Center for Liver, Digestive and Metabolic Diseases, University Medical Center Groningen and University of Groningen, Groningen.
Obesity (Silver Spring). 2013 Feb;21(2):361-6. doi: 10.1002/oby.20058.
Anti-oxidative properties of high density lipoproteins (HDL) are relevant for atheroprotection. HDL carry serum amyloid A (SAA), which may impair HDL functionality. We questioned whether HDL anti-oxidative capacity is determined by SAA.
Relationships of HDL anti-oxidative capacity (% inhibition of low density lipoprotein oxidation in vitro) with SAA were determined in 54 non-diabetic subjects without metabolic syndrome (MetS) and 68 subjects with MetS (including 51 subjects with Type 2 diabetes mellitus).
SAA levels were higher in MetS subjects, coinciding higher high sensitive C-reactive protein (hs-CRP) and lower HDL cholesterol and apolipoprotein (apo) A-I levels (P<0.001 for all). HDL anti-oxidative capacity was not different between subjects with and without MetS (P=0.76), but the HDL anti-oxidation index (HDL anti-oxidative capacity multiplied by individual HDL cholesterol concentrations), as a measure of global anti-oxidative functionality of HDL, was lower in Mets subjects (P<0.001). HDL anti-oxidative capacity was correlated inversely with SAA levels in subjects without MetS (r=-0.286, P=0.036). Notably, this relationship was independent of HDL cholesterol or apoA-I (P<0.05 for both). In contrast, no relation of HDL anti-oxidative capacity with SAA was observed in MetS subjects (r=0.032, P=0.80). The relationship of SAA with HDL anti-oxidative capacity was different in subjects with MetS compared to subjects without MetS (P=0.039 for the interaction between the presence of MetS and SAA on HDL anti-oxidative capacity) taking age and diabetes status into account.
Higher SAA levels may impair HDL anti-oxidative functionality. The relationship of this physiologically relevant HDL functionality measure with circulating SAA levels is apparently disturbed in metabolic syndrome.
高密度脂蛋白（HDL）的抗氧化特性与动脉粥样保护有关。HDL 携带血清淀粉样蛋白 A（SAA），这可能损害 HDL 的功能。我们质疑 HDL 的抗氧化能力是否由 SAA 决定。
在 54 名无代谢综合征（MetS）的非糖尿病患者和 68 名 MetS 患者（包括 51 名 2 型糖尿病患者）中，确定 HDL 抗氧化能力（体外低密度脂蛋白氧化的抑制百分比）与 SAA 的关系。
MetS 患者的 SAA 水平较高，同时伴有较高的高敏 C 反应蛋白（hs-CRP）和较低的 HDL 胆固醇和载脂蛋白（apo）A-I 水平（所有 P<0.001）。MetS 患者和非 MetS 患者的 HDL 抗氧化能力无差异（P=0.76），但作为 HDL 整体抗氧化功能的指标，HDL 抗氧化指数（HDL 抗氧化能力乘以个体 HDL 胆固醇浓度）在 MetS 患者中较低（P<0.001）。在无 MetS 的患者中，HDL 抗氧化能力与 SAA 水平呈负相关（r=-0.286，P=0.036）。值得注意的是，这种关系独立于 HDL 胆固醇或 apoA-I（两者均 P<0.05）。相比之下，在 MetS 患者中，HDL 抗氧化能力与 SAA 之间没有关系（r=0.032，P=0.80）。考虑到年龄和糖尿病状态，SAA 与 HDL 抗氧化能力的关系在 MetS 患者和非 MetS 患者中存在差异（P=0.039，MetS 和 SAA 对 HDL 抗氧化能力的交互作用）。
较高的 SAA 水平可能损害 HDL 的抗氧化功能。这种与生理相关的 HDL 功能测量与循环 SAA 水平的关系在代谢综合征中显然受到干扰。
